Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20169328 | 0.88 | MEN1 (0.42) | KCNN4MEN1KMT2ANPC1MAPT | |
| SCHEMBL12902478 | 0.83 | ESR1 (0.36) | KCNN4MEN1KMT2ANPC1MAPT | |
| SCHEMBL14272169 | 0.81 | PDE2A (0.46) | KCNN4MEN1KMT2ANPC1MAPT | |
| SCHEMBL18826628 | 0.81 | PDE2A (0.46) | KCNN4MEN1KMT2ANPC1MAPT | |
| SCHEMBL19480335 | 0.81 | TSHR (0.46) | KDM4EMEN1KMT2ANPC1MAPT | |
| Hydrochloric Acid SCHEMBL1239384 | 0.80 | KCNN4 (0.42) | KCNN4MEN1KMT2ANPC1MAPT | |
| SCHEMBL18896109 | 0.79 | ESR1 (0.44) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL7908310 | 0.79 | KCNN4 (0.40) | KCNN4KDM4ECYP17A1MEN1KMT2A | |
| SCHEMBL12038270 | 0.79 | TSHR (0.50) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL7267223 | 0.78 | LOXL2 (0.43) | KCNN4KMT2AHTTLOXL2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-08-02 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-07-18 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| EP-3215510-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073889-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20110318542-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition and Patterning Method Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110318542-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition and Patterning Method Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-6200993-B1 | ASTHMA; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | KCNN4 4616/4885KDM4E 710/4885CYP17A1 4227/4885 |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | KCNN4 4637/4885KDM4E 1027/4885CYP17A1 4199/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | KCNN4 4637/4885KDM4E 1027/4885CYP17A1 4199/4885 |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | KCNN4 4637/4885KDM4E 1027/4885CYP17A1 4199/4885 |
| US-20110318542-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition and Patterning Method Using Same | FRG1, AFF2, AFF1 | KCNN4 2817/4885KDM4E 2801/4885CYP17A1 3035/4885 |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | KCNN4 4671/4885KDM4E 944/4885CYP17A1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.